Home > Boards > US OTC > Medical - Equipment >

Cerebain Biotech Corp. (CBBT)

CBBT RSS Feed
Add CBBT Price Alert      Hide Sticky   Hide Intro
Moderator: Golden_Cross, Chrisny73, TAB78, treesus33, RarityLovesAll, RMS555
Search This Board: 
Last Post: 11/28/2020 10:46:37 PM - Followers: 284 - Board type: Free - Posts Today: 0

Cerebain Biotech Signs Letter of Intent with PKG, Inc.

https://www.otcmarkets.com/stock/CBBT/news/story?e&id=1677525

Cerebain Biotech acquire assets of PKG

Aug. 25, 2020 9:07 AM ET|About: Cerebain Biotech Corp. (CBBT)|By: Pranav Ghumatkar, SA News Editor 

Cerebain Biotech (OTCPK:CBBT) has entered into a letter of intent to purchase the assets of PKG.

With complete in-house vertical integration, PKG provides its customers with all of their product development needs from R&D, design & development, product testing and end of life product support and transitioning.

https://seekingalpha.com/news/3608531-cerebain-biotech-acquire-assets-of-pkg?utm_source=otcmarkets&utm_medium=referral

 

NMS Consulting Selected as Strategic Advisor to Cerebain Biotech Corp. for Acquisition Project

BEVERLY HILLS, CA / ACCESSWIRE / October 6, 2020 / NMS Consulting, Inc. ("NMS") is pleased to announce that it has been selected as strategic advisor by Cerebain Biotech Cop. (OTCPINK:CBBT) ("Cerebain") for its planned acquisition of PKG, Inc. ("PKG").

https://nmsconsulting.com/wp-content/uploads/2018/12/Logo-Full-Color-1.png

--------------------------------------------------------------------------------------------------------------------------------------------------------

About PKG

http://www.pkguis.com/

A CONTRACT DESIGN MANUFACTURER FOR
MEDICALGOVERNMENTAEROSPACE, AND INDUSTRIAL
INTERFACE SOLUTIONS.

http://www.pkguis.com/what-we-do

https://www.linkedin.com/company/pkg-user-interface-solutions

Pkg Inc.https://twitter.com/PKG_UIS

JonFrank Director of Sales PKG Inc.https://twitter.com/PKGUIS

------------------------------------------------------------------------------------------------------------------------------------------------
PKG Inc.’s CEO Excited With the Potential Acquisition by Cerebain Biotech

COSTA MESA, Calif.--(BUSINESS WIRE)-- Cerebain Biotech Corp. (OTC: CBBT), (the “Company” or “Cerebain”) previously announced, on August 25, 2020, that it had entered into a Letter of Intent to purchase the assets of PKG, Inc. (PKG).

Almir Garibovic, CEO of PKG Inc., stated “After 30 years in business, PKG, Inc. is thrilled that we have entered into a letter of intent to be acquired by Cerebain Biotech Corp. We are excited by this partnership because of our complementary strengths and it will enable us to fulfill our vision and values, while we continue to provide our customers with innovative design, technologies and manufacturing capabilities as never before.”

Eric Clemons, CEO of Cerebain, added "We are committed to evaluating both Companies strategic core competencies to enhance value for our shareholders while maintaining our focus on the continued development of Cerebain’s device for the treatment of Alzheimer’s Disease as well as aggressively managing PKG’s current operations."

About Cerebain Biotech Corp. Cerebain Biotech Corp. (OTC: CBBT) is a development-stage medical device company focused on the creation and clinical development of a minimally invasive implantable device and a synthetic drug solution. The device leverages the clinically observable, positive impact that Omentum stimulation has on cognitive function as related to dementias, and in particular, Alzheimer’s disease. The corporate vision is based on these positive clinical observations. Visit us at www.cerebain.com or connect with us on Twitter and Facebook to learn more.

About PKG Inc. PKG, Inc. was established in 1989 and is a privately held corporation based out of Meridian, ID. PKG, Inc. specializes in contract design, development, and manufacturing of system-level devices with expertise in human-machine interfaces. With experience in medical, aerospace, government, and industrial products, PKG helps to raise your company to the next level by leveraging our skills in engineering and technology integration across your product lines. With a complete in-house vertical integration of expertise, services, manufacturing processes, and technologies, PKG provides our customers with all of their product development and manufacturing needs. In addition to our expertise of system level devices and human machine interfaces, PKG also offers incubation and acceleration services for startup business and entrepreneurs.

----------------------------------------------------------------------------------------------------------------------------------------
 

PKG REGISTERS WITH FDA AND ANNOUNCES MANUFACTURING COMPLIANCE CERTIFICATION FROM TÜV SÜD

PKG, a privately-owned contract manufacturing and engineering company developing high-end medical and aerospace equipment, announced their registration with the FDA as an establishment producing medical personal
protection equipment (PPE), such as surgical masks. PKG also announced the completion of the transfer of its ISO 13485:2016 and ISO 9001:2015 compliance certificates
that encompasses the design, development, and production of its devices. 

 

The TÜV SÜD ISO 13485:2016 certification is for the contract design, development, and manufacture of non-implantable OEM system-level medical systems, subassemblies, and components for the areas of diagnostics,
imaging, patient treatment, monitoring, and surgical devices. This certification is from TÜV SÜD, one of the few organizations recognized as a designated body under the new European Medical Device Regulation (MDR).
It enables PKG to leverage its research, development, and manufacturing strengths for multiple new products addressing novel indications as we advance. TÜV SÜD’s MDR designation
will also ensure the continuity of regulatory compliance and support post-MDR implementation per European Union Directives on medical devices.

To Red More -> https://www.pkguis.com/news-content/2020/9/30/pkg-registers-with-fda-and-announces-manufacturing-compliance-certification-from-tv-sd


------------------------------------------------------------------------------------------------------------------------------------------
Latest Tweet from Eric

October 12 2020
Dear PKG Customer
.

I would like to thank all of you for the support and business you have provided to PKG over the last 30 years. We are progressing toward the final stages
of completing our acquisition of PKG, Inc. and we believe that it is very important to communicate our commitment to all of you.
 
Cerebain Biotech is fully committed to a smooth transition and we look toward to continuing to support your existing business as well as providing
you with innovative products and technologies going forward.
 
As of today, we are 1argeting the completion of the acquisition of PKG by mid-November of- 2020.  After the transaction completes_ PKG will continue business
as a subsidiary of Cerebain Biotech Corp. under the name PKG. Inc. Cerebain Bio1ech Is dedicated to growing and building future business around the
existing PKG brand and utilizing its already developed infrastructure. Resources, Quality Management Systems (QMS), ISO Certifications, and internal processes.
 
About Cerebain Biotech Corp.
 
Cerebain Biotech (OTCQB: CBBT) is a development - stage medical device company focused on the creation and clinical development of a minimally invasive implantable device
and a synthetic drug solution. The device leverages the clinically observable, positive impact that Omentum stimulation has on cognitive function as related to dementias,
and in particular, Alzheimer's disease. The corporate vision is based on these positive clinical observations.
 
We are extremely excited by this opportunity and we thank you for your patience as we work diligently on finalizing this acquisition.

Sincerely,
Eric Clemons
CEO

https://twitter.com/CerebainBiotech/status/1315916488147050496

------------------------------------------------------------------------------------------------------------------------------------------------

PKG Inc.’s CEO Excited With the Potential Acquisition by Cerebain Biotech

September 03, 2020 08:30 AM Eastern Daylight Time

COSTA MESA, Calif.--(BUSINESS WIRE)--Cerebain Biotech Corp. (OTC: CBBT), (the “Company” or “Cerebain”) previously announced, on August 25, 2020, that it had entered into a Letter of Intent to purchase the assets of PKG, Inc. (PKG).

“We are committed to evaluating both Companies strategic core competencies to enhance value for our shareholders while maintaining our focus on the continued development of Cerebain’s device for the treatment of Alzheimer’s Disease as well as aggressively managing PKG’s current operations.”

https://abs.twimg.com/errors/logo23x19.png";) -1px center no-repeat; float: left; font-size: 16px; margin: 10px 0px; padding: 3px 3px 3px 28px; border: none; outline: none medium !important;" rel="nofollow ugc">Tweet this

Almir Garibovic, CEO of PKG Inc., stated “After 30 years in business, PKG, Inc. is thrilled that we have entered into a letter of intent to be acquired by Cerebain Biotech Corp. We are excited by this partnership because of our complementary strengths and it will enable us to fulfill our vision and values, while we continue to provide our customers with innovative design, technologies and manufacturing capabilities as never before.”

Eric Clemons, CEO of Cerebain, added "We are committed to evaluating both Companies strategic core competencies to enhance value for our shareholders while maintaining our focus on the continued development of Cerebain’s device for the treatment of Alzheimer’s Disease as well as aggressively managing PKG’s current operations."

https://www.businesswire.com/news/home/20200903005085/en/PKG-Inc.%E2%80%99s-CEO-Excited-Potential-Acquisition-Cerebain

-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

TNS New Potential Home Run Report Available Now

September 03 2020 - 08:35AM
InvestorsHub NewsWire


New York, NY – September 3, 2020 -- InvestorsHub NewsWire – Traders News Source, a leading independent equity research and corporate access firm focused on small cap growth companies issues new research reports.

Cerebain Biotech Corp. (OTCPINK: CBBT) a development-stage medical device company focused on the creation and clinical development of a minimally invasive implantable device and a synthetic drug solution, has entered into a Letter of Intent to purchase the assets of PKG, Inc. (PKG). PKG, Inc. is a leading contract design, developer, and manufacturing company for system-level devices with expertise in human-machine interfaces focusing on healthcare, industrial, aerospace and government products.

https://ih.advfn.com/stock-market/USOTC/cerebain-biotech-pk-CBBT/stock-news/83193602/tns-new-potential-home-run-report-available-now

----------------------------------------------------------------------------------------------------------------------------------
 

PKG Inc. enters into an agreement with Adventus Ventures to finalize the development and manufacturing of the next-generation products for Allevion Therapeutics and Pressao Medical

 

PKG Inc.,

MERIDIAN, Idaho, October 5th, 2020 

PKG Inc. is pleased to announce a joint agreement with Adventus Venture, a medical device incubator, to finalize development and manufacturing plans for two companies in their portfolio: Allevion Therapeutics and Pressao Medical. PKG Inc. has been in business for over 30 years, developing complex and high-tech products for healthcare, aerospace, industrial, and government markets. In addition to the primary business model that supports Fortune 500 customers, PKG has heavily invested in developing infrastructure for the incubation and acceleration of start-up companies in the medical device sector.

To read more -> https://www.pkguis.com/news-content/2020/9/30/pkg-registers-with-fda-and-announces-manufacturing-compliance-certification-from-tv-sd-wglmd 
-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

MICROCAP DAILY

The Rise of Cerebain Biotech Corp OTCMKTS: CBBT) PKG LOI - October 7 2020

Cerebain Biotech Corp OTCMKTS: CBBT) has been running up the charts in recent weeks quickly attracting legions of shareholders and emerging as a volume leader in small caps as the Company
is in the process of acquiring PKG, Inc., a developer, and manufacturing company for system-level devices with expertise in human-machine interfaces
focusing on healthcare, industrial, aerospace and government products.


Read More ->  https://microcapdaily.com/the-rise-of-cerebain-biotech-corp-otcmkts-cbbt-pkg-loi/128112/

----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

INSIDER FINANCIALL

October 15 2020 - OTC Markets Stock News

MOMENTUM & GROWTH

Cerebain Biotech (CBBT) PKG Deal A Game-Changer

Cerebain Biotech (CBBT) has turned into a monster runner and a massive win for our subscribers that got our alert in September. Most of our subscribers have averaged in around $.002
and saw a huge run to $.012 this month. While some have booked profits and taken some money off the table, there’s still a lot more room for CBBT to run before the New Year.

Cerebain Biotech Daily Chart

The reason for the big run is the acquisition of PKG Inc. by Cerebain Biotech. PKG was doing $21 million in revenues before COVID-19 hit. This year PKG is estimated to post around $14 million in revenues
and then return to pre-COVID levels next year. With the acquisition expected to close next month, this puts Cerebain Biotech on track to being a revenue leader on the OTC Markets. This also makes shares of CBBT awfully cheap
under a penny. In this article, we take a look at the bull case for Cerebain Biotech and why this bull run is just getting started for CBBT.

Read More -> https://insiderfinancial.com/cerebain-biotech-cbbt-pkg-deal-a-game-changer/180547/
-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Reuters Does Report on Cerebain Biotech Corp. https://twitter.com/SamKnows7/status/1237803256845414402

Technology

Cerebain has a patent-pending device that is implanted in the omentum, a protective layer of skin that protects the abdominal organs. The device is designed to stimulate the omentum in patients with Alzheimer’s Disease. Omental stimulation has been shown to improve cognitive function in patients with dementias, including Alzheimer’s Disease.

Cerebain will evaluate the effect of omental stimulation at different intervals and levels of stimulation to determine the device’s ability to slow, stop or reverse the progression of Alzheimer’s Disease on patients.

About the Omentum

Generally described as a protective layer in the abdomen, the omentum covers the intestines, hangs on to the stomach and can be lifted like a flap. While the omentum is not a well-recognized body part, it can play important healing and protective roles for its host.

Protection: The omentum has abundant blood and lymphatic vessels, and can move flexibly throughout the abdomen to protect organs from threat and injury.

Healing: Additionally, it contains the largest supply of stem cells in the adult body. Because of its abundant blood supply, surgeons have long used the omentum to patch internal injuries sustained to other parts of the body.


Publications on the Omentum and it's Regenerative Powers

"Omentum a powerful biological source in regenerative surgery

""Regen Ther. 2019 Dec; 11: 182–191.    Published online 2019 Aug 8.""
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6700267/#

"Thinking Inside and Outside the Box: Intra- and Extra-Abdominal Use of the Amazing Omentum" Mar 8, 2019 
Bonnie Grambow Campbell, DVM, PhD, DACVS
College of Veterinary Medicine
Washington State University, Pullman, WA
https://www.vetfolio.com/learn/article/thinking-inside-and-outside-the-box-intra-and-extra-abdominal-use-of-the-amazing-omentum


FDA -SRO List - Detail

 

International Patent License

"" International Application Number PCT/US2009/031462 (published as WO 2009/0094340), titled “Omentum and Use Thereof”;""

https://www.sec.gov/Archives/edgar/data/1453099/000107878212000355/f8k020812_ex10z6.htm

Patent is a 20 Year Internatinal Agreement; ""Subject to the payment of fees under this title, such grant shall be for a term beginning on the date on which the patent issues and ending 20 years from the date on which the application for the patent was filed in the United States or""
https://www.law.cornell.edu/uscode/text/35/154

Cerebain’s Technology

Patent-pending technology has allowed for the development of a medical device that can
be implanted using a minimally invasive procedure.

Once implanted via what will probably be a same-day surgery procedure, patients may not have to undergo surgery again using this treatment method.

Cerebain has a manufacturing agreement with Sonos Medical, a trusted and reliable medical device supplier.

Clinical Trials

The Company is now in the process of preparing for initial clinical trials that will most likely occur at multiple medical centers in Europe.
 

Potential for a Personalized Approach to
Treatment for Alzheimer’s Disease Patients

As clinical trials are conducted and variables are put into play (e.g., frequency of stimulation, duration, location, etc.,) we may find that individuals respond differently and require individualized treatment plans. Cerebain’s device can potentially provide this, making our ability to positively impact the lives of as many Alzheimer’s Disease patients as possible.


In 2010 Cerebain Biotech licensed patent-pending technology for an implantable device that stimulates the omentum, and can be adjusted non-invasively to account for a range of factors, including frequency, strength of stimulation and location.

http://www.cerebain.com/

https://www.facebook.com/CerebainBiotech

https://twitter.com/cerebainbiotech

CBBT - Company Overview

Existing therapeutics have been unable to halt disease progression or extend life in a meaningful way

Cerebain’s novel device approach is supported by research and patient outcomes

Clinical evidence supports the Company’s working approach, that omentum stimulation improves cognitive function in patients with dementia, including Alzheimer’s Disease

Minimally invasive, one-time device implantation will overcome challenges associated with previous omentum stimulation procedures that are highly invasive

Patent-pending technology with broad applicability

Recent scientific breakthroughs regarding the potential identification of gene-specific protein increases prior to on-set of symptoms, could compliment our work

Early diagnosis is key to helping patients maintain quality of life http://www.nia.nih.gov/alzheimers/publication/alzheimers-disease-genetics-fact-sheet

Experienced management and advisory teams with the expertise to move the clinical program forward efficiently and effectively

News History

https://www.otcmarkets.com/stock/CBBT/news

Disclosures and Filings

https://www.otcmarkets.com/stock/CBBT/disclosure
 

OTCQB Certification

https://backend.otcmarkets.com/otcapi/company/financial-report/180313/content
 

Corporate Leadership

 

Eric Clemons, President and CEO
e-mail:  clemons@cerebain.com

Mr. Clemons has a long history building and growing companies across multiple industries. Prior to assuming leadership of Cerebain, he served as President and Chief Operating Officer for GTC Telecom Corp, a publicly traded Nevada Corporation that operated out of Costa Mesa, CA. During his tenure, Mr. Clemons was instrumental in growing the company’s annual revenues from $500,000 per year to over $17 million per year.

It was Cerebain technology, which offers a completely new way of approaching the development of an effective Alzheimer’s disease treatment that captured Mr. Clemons’ imagination, triggering his move into the life sciences arena.

“While there have been some very recent key learnings in the Alzheimer’s treatment space, the fact is that the disease remains the only top ten killer in the United States with no effective treatments currently available and no way to halt or slow progression,” Clemons said. “We are hopeful that our device, which will focus on the impact of omental stimulation and cognitive function in Alzheimer’s Disease patients, can change that.”

Wesley Tate – former - Chief Financial Officer
e-mail:  wtate@cerebain.com

Prior to joining Cerebain Biotech, Mr. Tate was the owner of Strategic Business Associates, a Tennessee-based consultancy offering business management and growth services to start-up and early-stage companies.

Over the course of his career Mr. Tate has held key managerial positions at both healthcare and telecoms companies. This includes Chief Financial Officer for HST Global, Inc., a development-stage biotechnology company located in Virginia; and Executive Vice President and Chief Operating Officer for InnerLight Inc., a life science company located in Utah.

Mr. Tate received his Bachelor of Science degree from the University of Tennessee, Knoxville, with majors in Finance and Psychology, and earned his Masters of Business Administration from the University of Tennessee, Knoxville, with concentrations in Finance and Management.

He is proud to have served his country as a member of the United States Army.

Mr. Tate resigned from Cerebain in July of 2019, he did however agree to assist in any way possible during the transition period, as best as anyone has been able to determine, he is still functioning at CBBT is some sort or manner.

Cerebain engaged with NMS Consulting  - 

""NMS Consulting will also advise Cerebain on a corporate restructuring and cost savings plan, under which it will identify opportunities to optimize operations, drive efficiency and reduce costs.""

 

https://www.businesswire.com/news/home/20181204005563/en/Cerebain-Initiates-Repositioning-Review-Business-Corporate-Strategic

NMS Consultinghttp://www.nms-consulting.com/

Global Advisorshttp://www.globalviewadvisors.com/our-clients/

-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

About the Omentum

 

Omental Transposition to the Brain for Alzheimer's Disease

First published: 17 December 2006        https://doi.org/10.1111/j.1749-6632.1997.tb48483.x     Citations: 13

Abstract

ABSTRACT: Omental transposition (OT) to revascularize the brain was first performed in animals in the late 1960s, where it was shown that blood vessels originating from the omentum crossed through the omental-cerebral interface prior to developing into large-sized vessels that penetrated directly and deeply into the underlying brain. The additional cerebral blood flow coming from the omentum was of sufficient volume to protect an animal's brain from cerebral infarction even in the presence of middle cerebral artery ligation. It was also learned that the omentum was a rich source for neurotransmitters and omentum-derived nerve growth substance. OT to the brain is now being done for a variety of conditions which include strokes, TIAs, epilepsy, and Parkinson's disease. Of recent interest is the published information that OT may play some role in Alzheimer's disease (AD). The placement of the omentum on an AD brain has led to a profound decrease in senile plaque formation. The omentum may ultimately prove to be beneficial in reversing or at least stabilizing the dementia associated with the devastation of AD.

https://nyaspubs.onlinelibrary.wiley.com/doi/full/10.1111/j.1749-6632.1997.tb48483.x

----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Omental transposition for Alzheimer’s disease

Pages 103-108 | Accepted 01 Sep 1995, Published online: 21 Jul 2016       https://doi.org/10.1080/01616412.1996.11740387

 

A patient with Alzheimer’s disease of long standing was treated with omental transposition to his brain. The rational for the procedure was to use the omentum to increase cerebral blood flow and to augment cholinergic neurotransmission activity. The patient improved for a year following surgery but after that time slowly began to decline neurologically and cognitively. However; according to Alzheimers specialists who have followed the patient pre and post- operatively he still maintains, 2.5 years after surgery a higher level of performance than expected. There is theoretical and now a clinical suggestion that the omentum might play some role in the treatment of Alzheimer’s disease. In view of the devastating nature of, the disease, it seems reasonable to suggest that a limited controlled study be carried out to support or negate the benefit of the operation. [Neurol Res 1996; 18: 103–108]

https://www.tandfonline.com/doi/abs/10.1080/01616412.1996.11740387
------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

I very informative post https://investorshub.advfn.com/boards/read_msg.aspx?message_id=159238893 that should be read

OTCShotCaller   Saturday, 10/31/20 09:36:12 PM
Re: None 0
Post #  of 20208 
 
Human Omentum - Cellular Basis For Tissue Re-generation

Apparently CBBT is in the process of harnessing the Human Omentum's known capacity for cellular regeneration, an already PROVEN FACT!

What this untapped area of Applied Biotechnology represents qualifies as "Disruptive Technology."

Human Omentum has been repeatedly shown to have the capacity to cause cellular regeneration & repair of various organs in the body including NEURONS!!! I posted several links on this yesterday 10/30/20 of several studies verifying the ability of human omentum to increase cerebral blood flow in brain tissue which in turn favors sustained neuron viability, and theoretically helps prevent the on-set or progress of Alzheimer's symptoms.

One study even showed that if arterial supply to a region of the brain is "tied off" by a surgeon, and then Human Omentum is placed over the area of the brain that the tied off artery supplied, the brain cells in that region of the brain continue to thrive as if the artery supply was never interrupted.

This finding is like something out of a science fiction movie, totally unheard of, totally unexplained, AND it likely represents one of the greatest scientific-medical discovery of modern medicine which CBBT has tapped into with the development of a viable and effective treatment for Alzheimer's.

Know this, Alzheimer's is all about brain cell (neurons) atrophy and death related to decreased blood flow to brain cell tissues with aging. Other mechanisms are involved but this is the primary cause. Nutrients also play a big role in neuron survival and thriving which human omentum highly supports because it's one of the richest nutrient sources in the human body.

Therefore with it's combined effect of causing increased blood flow brain cell tissue in tandem with delivery of high potency nutrients, these forces operating together have the capacity to preserve brain cell function in aging individuals.

This is what CBBT is up to in their Patent development for treating Alzheimer's and as a doctor I believe they are definitely on the right track.

Here's a very brief but major eye-opener video on this topic:

https://www.youtube.com/watch?v=4k7AZlYef_o

Be well and prosper ...

 

A/S  1,250,000,000   11/16/2020

O/S    684,643,377   11/16/2020

Restricted 5,529,037  11/16/2020

Unrestricted 679,114,340  11/16/2020

Held at DTC 677,609,839 11/16/2020

Float   4,040,310    09/26/2018 ** See comment's below **

https://www.otcmarkets.com/stock/CBBT/security

The below Float number's cannot be verified, but as of the dates stated, that is what the individual website showed

Float per yahoo.Finance  139.81M  18 Oct 2020 https://finance.yahoo.com/quote/CBBT/key-statistics?p=CBBT
Float per TDA  138.2M 18 Oct 2020<a data-cke-saved-href="https://research.tdameritrade.com/grid/public/research/stocks/fundamentals?symbol="; href="https://research.tdameritrade.com/grid/public/research/stocks/fundamentals?symbol="; cbbt""="" rel="nofollow ugc" target="_blank">https://research.tdameritrade.com/grid/public/research/stocks/fundamentals?symbol="CBBT";"; rel="nofollow ugc" target="_blank">https://research.tdameritrade.com/grid/public/research/stocks/fundamentals?symbol=CBBT"; rel="nofollow ugc"> https://research.tdameritrade.com/grid/public/research/stocks/fundamentals?symbol=CBBT

 

CBBT - Historical Prices /  Volume

https://ih.advfn.com/stock-market/USOTC/cerebain-biotech-pk-CBBT/historical/more-historical-data

 

 

CBBT
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
PostSubject
#20838  Sticky Note Cerebain Biotech Announces General Business Update BubbaCheese 11/12/20 10:30:26 AM
#20630  Sticky Note From: Investor Relations <ir@cerebain.com> TAB78 11/09/20 03:06:14 PM
#18358  Sticky Note FUNDAMENTALS RULE.... fly_fisherman 10/15/20 10:36:08 AM
#18323  Sticky Note $CBBT article https://insiderfinancial.com/cerebain-biotech-cbbt-pkg-deal-a-game InsiderFinancial 10/15/20 04:37:46 AM
#18254  Sticky Note $CBBT article https://microcapdaily.com/the-rise-of-cerebain-biotech-corp-otcmkt Joseph88 10/14/20 07:37:24 AM
#18141  Sticky Note PKG Customers updated on acquisition !!! fly_fisherman 10/12/20 11:18:23 PM
#21497   I will admit I was wrong as hell 2stubborn2quit 11/28/20 10:46:36 PM
#21496   Yep CBBT updated share structure again, not changes TAB78 11/28/20 09:57:40 PM
#21495   When was the last time CBBT did TAB78 11/28/20 09:55:49 PM
#21494   Yes indeed on both posts, and CBBT is TAB78 11/28/20 09:52:20 PM
#21493   And your point is what???? Thats OT, TAB78 11/28/20 09:39:00 PM
#21492   U Know it, :) TAB78 11/28/20 08:07:44 PM
#21491   Yep it was in the news release as TAB78 11/28/20 08:05:29 PM
#21490   Journal of Alzheimers Disease & Parkinsonism Open Access Omental transposition Steve Miller 11/28/20 07:46:31 PM
#21489   Cbbt top rated! Quality stock ChallengeTheGoal 11/28/20 06:47:26 PM
#21488   I agree completely... fly_fisherman 11/28/20 11:31:24 AM
#21487   I am very happy about the progress Cerebain RMS555 11/28/20 10:09:10 AM
#21486   Did you notice on PKG's site, the MerrillSam 11/28/20 10:05:30 AM
#21485   Nice information! I live in Lexington Ky. That allenc 11/27/20 10:20:22 PM
#21484   TY for posting the paragraph TAB78 11/27/20 09:52:26 PM
#21483   This company says it makes the first FDA-approved falon 11/27/20 08:08:06 PM
#21482   Over the next few weeks, PKG Inc. intends jeffhortons 11/27/20 08:06:07 PM
#21481   Reread first sentence of paragraph 7 of the TAB78 11/27/20 06:19:59 PM
#21480   Nice find, TAB78 11/27/20 06:14:13 PM
#21479   Very Sorry. Old news. judypudy 11/27/20 03:53:41 PM
#21478   I saw this posted on Twitter... judypudy 11/27/20 03:01:17 PM
#21477   An impressive outreach using the Clear Mask for MerrillSam 11/27/20 02:11:33 PM
#21476   Closed @ .0175 on Wed. Opened up today TAB78 11/27/20 01:27:07 PM
#21475   Yes Judy, good reminder for folks, its now xlosed TAB78 11/27/20 01:09:36 PM
#21474   have a good weekend fam RarityLovesAll 11/27/20 12:59:05 PM
#21473   nice bid ;) RarityLovesAll 11/27/20 12:06:34 PM
#21472   Know if Ihub is going to do happy fink 11/27/20 12:03:07 PM
#21471   I'm out of here for the day. Enjoy allenc 11/27/20 11:49:59 AM
#21470   CBBT- This statement from the latest PR tells allenc 11/27/20 11:48:04 AM
#21469   Hey Sello. Good to see you here. Look allenc 11/27/20 11:39:40 AM
#21468   buys are over double sells market RarityLovesAll 11/27/20 11:34:45 AM
#21467   Like it sello 11/27/20 11:23:13 AM
#21466   nice hits on this huge wall! RarityLovesAll 11/27/20 11:19:04 AM
#21465   For those who forgot...short trading session today. Market judypudy 11/27/20 11:04:07 AM
#21464   That was a dirty trick on the .0173 TAB78 11/27/20 10:52:48 AM
#21463   Great! Maybe you could provide some feedback allenc 11/27/20 10:52:43 AM
#21462   Agree, i loving watching, can't wait until i TAB78 11/27/20 10:50:41 AM
#21461   CBBT- Link to PKG Inc. website. The company allenc 11/27/20 10:50:21 AM
#21460   Yep the wall was a trader trying to TAB78 11/27/20 10:49:18 AM
#21459   Yes indeed, she is very bullish, peeps got TAB78 11/27/20 10:47:52 AM
#21458   Definitely good to watch L2 just to get allenc 11/27/20 10:47:44 AM
#21457   CBBT .02 breaking shortly, imo x-ray-eyes 11/27/20 10:47:39 AM
#21456   Yep, agree they gonna lose on this one, TAB78 11/27/20 10:46:08 AM
#21455   I ordered my mask's today. DLJohnson 11/27/20 10:44:45 AM
#21454   Jockeying for Position... fly_fisherman 11/27/20 10:44:11 AM
#21453   I agree with ya, yep day to day, TAB78 11/27/20 10:43:34 AM
#21452   yeah more than likely, jokes on them we RarityLovesAll 11/27/20 10:43:10 AM
#21451   I am thinking the wall of 600k - TAB78 11/27/20 10:41:11 AM
#21450   Not to concerned about the day to day allenc 11/27/20 10:41:06 AM
#21449   Bids building / Ask shrinking TAB78 11/27/20 10:36:14 AM
#21448   Yep, agreed made that mistake before,.paid for it TAB78 11/27/20 10:34:13 AM
PostSubject
Consent Preferences